Franklin Biotechnology Discovery has an experienced team at the helm, but it needs to distinguish itself.
Franklin Biotechnology Discovery A FBDIX
- NAV / 1-Day Return 131.27 / −0.17 %
- Total Assets 902.3 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.070%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 1,000
- Status Open
- TTM Yield —
- Turnover 24%
USD | NAV as of Apr 16, 2024 | 1-Day Return as of Apr 16, 2024, 10:11 PM GMT+0
Morningstar’s Analysis FBDIX
Will FBDIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 38.3
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Amgen Inc | 6.64 | 63.9 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 6.25 | 60.1 Mil | Healthcare |
Franklin IFT Money Market | 5.28 | 50.8 Mil | Cash and Equivalents |
Vertex Pharmaceuticals Inc | 5.21 | 50.1 Mil | Healthcare |
Ascendis Pharma A/S ADR | 3.91 | 37.6 Mil | Healthcare |
Gilead Sciences Inc | 3.03 | 29.1 Mil | Healthcare |
Biogen Inc | 2.92 | 28.1 Mil | Healthcare |
Intra-Cellular Therapies Inc | 2.80 | 26.9 Mil | Healthcare |
AstraZeneca PLC ADR | 2.64 | 25.4 Mil | Healthcare |
Jazz Pharmaceuticals PLC | 2.52 | 24.2 Mil | Healthcare |